$0.00 $0.00 (0.0%)

12:00 AM EST on 01/01/01

Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 1 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Current Price $0.00 Mkt Cap $0.00
Open $0.00 P/E Ratio 0.00
Prev. Close $0.00 Div. (Yield) $0.00 (0.0%)
Daily Range $0.00 - $0.00 Volume
52-Wk Range $0.00 - $0.00 Avg. Daily Vol.

Caps

How do you think NASDAQ:KERX will perform against the market?

Add Stock to CAPS Watchlist

All Players

368 Outperform
60 Underperform
 

All-Star Players

23 Outperform
21 Underperform
 

Wall Street

1 Outperform
0 Underperform
 

Top NASDAQ:KERX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

carterhiggins (83.24)
Submitted April 04, 2017

This company has a drug that will help patients before they get to complete renal failure. The drug is currently only in use by dialysis patients, once they get general approval for patients that are starting renal failure - the number of possible… More

TerryHogan (99.97)
Submitted October 03, 2018

Just judging by the financials summaries here on the fool, I'd guess this thing is run by either scientists or lawyers. Better off having a numbers person, or maybe an operations person at the helm. Even a people person can work depending on the… More

Recent Community Commentary

Read the most recent pitches from players about KERX.

Recs

1
Member Avatar TerryHogan (99.97) Submitted: 10/3/2018 12:56:35 AM : Underperform Start Price: $3.17 NASDAQ:KERX Score: +7.19

Just judging by the financials summaries here on the fool, I'd guess this thing is run by either scientists or lawyers. Better off having a numbers person, or maybe an operations person at the helm. Even a people person can work depending on the business. But I don't think that's what's going on here.

Recs

0
Member Avatar TMFEBCapital (90.55) Submitted: 10/18/2017 3:22:36 PM : Outperform Start Price: $6.62 NASDAQ:KERX Score: -78.74

Potential opportunity to significantly expand addressable market with pending FDA label approval in non-dialysis patients. 62 million plus from Aurixia this year, representing 25% YoY plus quarterly growth Q3/Q4. FDA PDUFA date Nov. 6.

Recs

1
Member Avatar carterhiggins (83.24) Submitted: 4/4/2017 6:12:24 PM : Outperform Start Price: $5.79 NASDAQ:KERX Score: -82.25

This company has a drug that will help patients before they get to complete renal failure. The drug is currently only in use by dialysis patients, once they get general approval for patients that are starting renal failure - the number of possible patients will go up 5 fold at least.

Leaderboard

Find the members with the highest scoring picks in KERX.

Score Leader

empreinte

empreinte (34.44) Score: +623.72

The Score Leader is the player with the highest score across all their picks in KERX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
MTF108 63.20 8/28/2006 Underperform 3W $12.05 -72.12% +172.41% +244.53 0 Comment
Darbhanga 48.01 5/5/2010 Underperform 3M $6.08 -44.72% +182.42% +227.14 0 Comment
Made4WallStreet 67.17 12/29/2006 Underperform 1Y $13.39 -74.91% +147.59% +222.50 0 Comment
vbaci 29.00 8/24/2010 Underperform 5Y $3.68 -8.70% +212.41% +221.10 0 Comment
Korodas 67.97 9/1/2010 Underperform NS $3.72 -9.68% +205.92% +215.60 0 Comment
zokes10 29.57 4/13/2010 Underperform NS $4.82 -30.29% +176.32% +206.61 0 Comment
zokes101 30.19 4/13/2010 Underperform NS $4.79 -29.85% +176.68% +206.54 0 Comment
CHICAGOREALTOR < 20 4/14/2010 Underperform 5Y $4.65 -27.74% +175.50% +203.24 0 Comment
supez2004 < 20 3/3/2008 Underperform NS $5.75 -41.57% +159.36% +200.92 2 Comments
stockjock11 51.71 4/22/2010 Underperform NS $4.19 -19.81% +176.55% +196.36 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for KERX.